These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25534380)

  • 1. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis.
    Jenkins MA; Dowty JG; Ait Ouakrim D; Mathews JD; Hopper JL; Drouet Y; Lasset C; Bonadona V; Win AK
    J Clin Oncol; 2015 Feb; 33(4):326-31. PubMed ID: 25534380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
    Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
    JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.
    Kastrinos F; Stoffel EM; Balmaña J; Steyerberg EW; Mercado R; Syngal S
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2044-51. PubMed ID: 18708397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.
    Capelle LG; Van Grieken NC; Lingsma HF; Steyerberg EW; Klokman WJ; Bruno MJ; Vasen HF; Kuipers EJ
    Gastroenterology; 2010 Feb; 138(2):487-92. PubMed ID: 19900449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.
    Järvinen HJ; Renkonen-Sinisalo L; Aktán-Collán K; Peltomäki P; Aaltonen LA; Mecklin JP
    J Clin Oncol; 2009 Oct; 27(28):4793-7. PubMed ID: 19720893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.
    Vasen HF; Abdirahman M; Brohet R; Langers AM; Kleibeuker JH; van Kouwen M; Koornstra JJ; Boot H; Cats A; Dekker E; Sanduleanu S; Poley JW; Hardwick JC; de Vos Tot Nederveen Cappel WH; van der Meulen-de Jong AE; Tan TG; Jacobs MA; Mohamed FL; de Boer SY; van de Meeberg PC; Verhulst ML; Salemans JM; van Bentem N; Westerveld BD; Vecht J; Nagengast FM
    Gastroenterology; 2010 Jun; 138(7):2300-6. PubMed ID: 20206180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for breast cancer as an integral part of Lynch syndrome.
    Buerki N; Gautier L; Kovac M; Marra G; Buser M; Mueller H; Heinimann K
    Genes Chromosomes Cancer; 2012 Jan; 51(1):83-91. PubMed ID: 22034109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
    Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
    J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
    Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
    Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of less common cancers in proven mutation carriers with lynch syndrome.
    Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
    J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors Associated with Colorectal Cancer in a Subset of Patients with Mutations in MLH1 and MSH2 in Taiwan Fulfilling the Amsterdam II Criteria for Lynch Syndrome.
    Kamiza AB; Hsieh LL; Tang R; Chien HT; Lai CH; Chiu LL; Lo TP; Hung KY; Wang CY; You JF; Hsiung CA; Yeh CC
    PLoS One; 2015; 10(6):e0130018. PubMed ID: 26053027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
    Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK
    J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA repair gene polymorphisms and risk of early onset colorectal cancer in Lynch syndrome.
    Reeves SG; Meldrum C; Groombridge C; Spigelman A; Suchy J; Kurzawski G; Lubinski J; Scott RJ
    Cancer Epidemiol; 2012 Apr; 36(2):183-9. PubMed ID: 21974800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of MLH1 and MSH2 mutations in Lynch syndrome.
    Balmaña J; Stockwell DH; Steyerberg EW; Stoffel EM; Deffenbaugh AM; Reid JE; Ward B; Scholl T; Hendrickson B; Tazelaar J; Burbidge LA; Syngal S
    JAMA; 2006 Sep; 296(12):1469-78. PubMed ID: 17003395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer.
    Wijnen JT; Vasen HF; Khan PM; Zwinderman AH; van der Klift H; Mulder A; Tops C; Møller P; Fodde R
    N Engl J Med; 1998 Aug; 339(8):511-8. PubMed ID: 9709044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
    Alemayehu A; Sebova K; Fridrichova I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium.
    Goecke T; Schulmann K; Engel C; Holinski-Feder E; Pagenstecher C; Schackert HK; Kloor M; Kunstmann E; Vogelsang H; Keller G; Dietmaier W; Mangold E; Friedrichs N; Propping P; Krüger S; Gebert J; Schmiegel W; Rueschoff J; Loeffler M; Moeslein G;
    J Clin Oncol; 2006 Sep; 24(26):4285-92. PubMed ID: 16908935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.